Catalogue Catalogue
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Pharmacotherapy-Enhancing Drugs
EDITORIAL NOTE Pharmacotherapy-Enhancing drugs Robin Karli* Karli R. Pharmacotherapy-Enhanced drugs. Clin Pharmacol Toxicol Res. 2021;4(2):1. DESCRIPTION Pharmacotherapy is related to several diseases and disorders. The medication varies from one disease or disorder to the other. Pharmacotherapy is provided to diseases and disorders related to Cardiovascular, respiratory, n the treatment of addiction, medications are wanted to reduce the gastrointestinal, renal, neurological, psychiatric, endocrinologic, gynecologic I intensity of withdrawal symptoms, reduce alcohol and other drug craving and obstetric, urological, immunologic, rheumatologic, ophthalmic, and reduce the likelihood of use or relapse for specific drugs by blocking dermatologic, hematologic, infectious diseases, oncologic and nutritional their effect. The primary goal of medication-assisted treatment is for the disorders. patient to achieve fully-sustained remission. SELECTION OF AN ANTIDEPRESSANT MEDICATION Pharmacotherapy is therapy using pharmaceutical drugs, as distinguished from therapy using surgery (surgical therapy), radiation (radiation therapy), movement (physical therapy), or other modes. Among The overall effectiveness of antidepressant medications is usually equivalent between and within classes of medicines. However, there are distinct physicians, sometimes the term medical therapy refers specifically to differences in individual patient response to and side effects caused by the pharmacotherapy as against surgical or other therapy; as an example, in classes of medicines and individual agents. The genetic differences within the oncology, medical oncology is thus distinguished from surgical oncology. metabolism of certain medications including antidepressants are often Pharmacists are experts in pharmacotherapy and are liable for ensuring determined by cytochrome P450 genetic testing. This testing may identify the safe, appropriate, and economical use of pharmaceutical drugs. -
We've Got Your Pre-Reg Year Covered
We’ve got your pre-reg year covered Don’t forget RPS members receive at least 25% off, simply enter your membership number at the checkout. Order online at www.pharmpress.com/pre-registration Books to support you through Pharmacy Registration Clinical Pharmacy Pocket Assessment Questions Companion NEW EDITION Second edition Second edition Edited by Nadia Bukhari, Oksana Pyzik Edited by Alistair Howard Gray, Jane Wright, Lynn Bruce, Jennifer Oakley Written in compliance with the current GPhC registration exam guidelines, this essential title helps students prepare A handy pocket sized A-Z book that offers quick and reliable for their registration exam. With 400 brand new questions, answers to everyday pharmacy questions. This edition is it features single best answer, extended MCQs and extremely useful for trainees, whether you work in a hospital calculation questions. or community setting. ISBN: 978 0 85711 278 1 • £32 ISBN: 978 0 85711 157 9 • £32 Paperback • 180 x 100mm • 568pp • 2015 Paperback • 216 x 138mm • 224pp • Feb 2017 BNF Hospital Pre-registration March and September Pharmacist Training Joint Formulary Committee Aamer Safdar, Shirley Ip One of the essential references you will need to understand With tips, hints, past experiences and anecdotes from the and navigate ahead of your exam. Published each March authors in their roles as pre-registration tutors, this accessible and September, the BNF provides up-to-date guidance on book provides encouragement and guidance throughout the prescribing, dispensing and administering medicines. pre-registration process. It covers topics such as looking for It reflects current best practice as well as legal and your first job, making the transition from student to professional guidelines relating to the use of medicines. -
Updated Pharmacy Technician Duties Policy and Procedure #140
Approved Technician Duties Policy and Procedure #140 An employee of a pharmacy holding a pharmacy permit not registered with the SC Board of Pharmacy may perform many clerical functions associated with the practice of pharmacy. A non-registered employee is prohibited from performing the following functions: • Entering data beyond demographic information (name, address, date of birth, gender, contact information, insurance, etc) • Interpreting prescription drug orders • Handling non-dispensed legend drugs or devices. • Compounding of any over-the-counter or legend drug A Registered or Certified Pharmacy Technician may perform many clerical functions associated with the practice of pharmacy at a facility holding a pharmacy permit. While fulfilling clerical functions, up to the point of dispensing requiring clinical interpretation and/or product selection, as defined in Section 40-43-30(15), registered or certified technicians would not be considered in the pharmacist to technician ratio as indicated by Sec. 40-43-86 (B)(4)(b). A Registered Pharmacy Technician may perform many technical functions associated with the practice of pharmacy at a facility holding a pharmacy permit; however, even under the direct supervision of a pharmacist, the pharmacy technician is prohibited from performing the following functions: • Performing any duty required by law or regulation to be performed by a state- certified technician, pharmacy intern or extern, or a pharmacist • Administering immunizations • Counseling a patient on a new or refill prescription -
Current Practices of Obesity Pharmacotherapy, Bariatric Surgery Referral and Coding for Counselling by Healthcare Professionals Christine Petrin, Scott Kahan, M
Obesity Science & Practice doi: 10.1002/osp4.53 ORIGINAL ARTICLE Current practices of obesity pharmacotherapy, bariatric surgery referral and coding for counselling by healthcare professionals Christine Petrin, Scott Kahan, M. Turner, C. Gallagher and W. H. Dietz George Washington University, Summary Washington, DC, USA Introduction Received 21 April 2016; revised 7 June 2016; accepted 9 June 2016 Rates of obesity pharmacotherapy use, bariatric surgery and intensive behavioural counselling have been extremely low. Address for correspondence: C Petrin, Objectives George Washington University, 950 New Hampshire Ave NW Suite 300, Washington, DC 20037, USA. E-mail: cepetrin@gwmail. The primary objective of this study was to survey healthcare provider beliefs, practice gwu.edu and knowledge regarding obesity management. Methods Primary care physicians (PCPs), OB-GYN physicians and nurse practitioners (NPs) responded to a web-based survey related to drug therapy practice, bariatric surgery referral and reimbursement coding practice. Results Rates of reported use of obesity pharmacotherapy appear to be increasing among PCPs, which is likely related to the approval of four new obesity pharmacotherapy agents since 2012. Rates of pharmacotherapy use among OB-GYNs and NPs appear much lower. Similarly, few PCPs are averse to recommending bariatric surgery, but aversion among OB-GYNs and NPs is significantly higher. Conclusion Together, these observations suggest that OB-GYN and NP populations are important targets for education about obesity management. Very few PCPs, OB-GYNs or NPs use behavioural counselling coding for obesity. Better understanding of why this benefit is not being fully used could inform outreach to improve counselling rates. Keywords: Bariatric surgery referral, CPT coding, obesity counselling, obesity pharmacotherapy. -
Supplemental Table
RUPRI Center for Rural Health Policy Analysis Rural Policy Brief Supplement Brief No. 2017-4 APRIL 2017 www.public-health.uiowa.edu/rupri Telepharmacy Rules and Statutes: A 50-State Survey Table Supplement to Brief No. 2017-4 State Restrictions of Telepharmacy where Legislatively or Administratively Authorized, August 2016 State Geographic Restrictions Facility Restrictions Permitted Providers Staffing Requirements Inter-State Accessibility Alaska Located at least 10 road miles from Not telepharmacy specific. Pharmacist, pharmacy Not telepharmacy specific. Not telepharmacy specific. any non-remote pharmacy unless technician, pharmacy federal law prohibits non-remote intern. pharmacy from providing pharmacy (12 AAC 52.425 (c)(1)) services to individuals within the area. (12 AAC 52.423(b)(2)) Colorado Located at least 20 miles from any Not telepharmacy specific. Pharmacist; pharmacy Not telepharmacy specific. Not telepharmacy specific. pharmacy or telepharmacy outlet. technician. (12-42.5-102(39.5)(a)(II)) (12-42.5- 102(39.5)(a)(IV)) Hawaii Located at least 5 miles from any Not telepharmacy specific. Pharmacist; qualified Not telepharmacy specific. Not telepharmacy specific. pharmacy except for remote remote dispensing dispensing pharmacy established technician. prior to July 3, 2008 that has §461-10.5(a)(2) previously dispensed and will continue to dispense only prescription medications acquired pursuant to section 340B of the Public Health Service Act, Title 42 United States Code section 256b. (§461-10.5(c)(1)) Idaho 1) The Board will consider the Remote dispensing site must be Pharmacist; pharmacist 1) Unless staffed by a pharmacist, a Not telepharmacy specific. availability of pharmacists, the located in a technician. -
Pharmacotherapy Program Description 2020-2021
PGY 1 & PGY 2 Pharmacotherapy Residency AMARILLO PROGRAM SUMMARY 2020-2021 !1 of 8! PGY 1 & PGY 2 PHARMACOTHERAPY - AMARILLO PURPOSE PGY1 Program PGY1 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and outcomes to contribute to the development of clinical pharmacists responsible for medication-related care of patients with a wide range of conditions, eligible for board certification, and eligible for postgraduate year two (PGY2) pharmacy residency training. PGY2 Program PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available. INTRODUCTION The PGY1/PGY2 Pharmacotherapy Residency is designed to produce a specialized practitioner with an advanced degree of proficiency and expertise in working with interdisciplinary teams to deliver comprehensive patient care to diverse populations from ambulatory care to critically ill, pediatric to geriatric ages, and presenting with varied and complex health problems. -
ASHP Statement on Pharmaceutical Care
Medication Therapy and Patient Care: Organization and Delivery of Services–Statements 331 ASHP Statement on Pharmaceutical Care The purpose of this statement is to assist pharmacists in under- Care. Central to the concept of care is caring, a personal standing pharmaceutical care. Such understanding must pre- concern for the well-being of another person. Overall cede efforts to implement pharmaceutical care, which ASHP patient care consists of integrated domains of care including believes merit the highest priority in all practice settings. (among others) medical care, nursing care, and pharmaceu- Possibly the earliest published use of the term pharma- tical care. Health professionals in each of these disciplines ceutical care was by Brodie in the context of thoughts about possess unique expertise and must cooperate in the patient’s drug use control and medication-related services.1,2 It is a overall care. At times, they share in the execution of the various term that has been widely used and a concept about which types of care (including pharmaceutical care). To pharma- much has been written and discussed in the pharmacy pro- ceutical care, however, the pharmacist contributes unique fession, especially since the publication of a paper by Hepler knowledge and skills to ensure optimal outcomes from the and Strand in 1990.3–5 ASHP has formally endorsed the con- use of medications. cept.6 With varying terminology and nuances, the concept At the heart of any type of patient care, there exists a has also been acknowledged by other national pharmacy or- one-to-one relationship between a caregiver and a patient. -
Pharmacy Services in Telepharmacy: How’S It Working, Where It’S Working, and What’S Required to Practice in This New Setting
Advances in Pharmacy: Journal of Student Solutions to Pharmacy Challenges Volume 1 | Issue 1 Article 5 2017 Pharmacy Services in Telepharmacy: how’s it working, where it’s working, and what’s required to practice in this new setting. Aimee Skrei University of Minnesota - Twin Cities, [email protected] Michelle M. Rundquist [email protected] Follow this and additional works at: http://pubs.lib.umn.edu/advances Recommended Citation Skrei, Aimee and Rundquist, Michelle M. (2017) "Pharmacy Services in Telepharmacy: how’s it working, where it’s working, and what’s required to practice in this new setting.," Advances in Pharmacy: Journal of Student Solutions to Pharmacy Challenges: Vol. 1 : Iss. 1 , Article 5. Available at: http://pubs.lib.umn.edu/advances/vol1/iss1/5 This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License Advances in Pharmacy: Journal of Student Solutions to Pharmacy Challenges is published by the University of Minnesota Libraries Publishing. Pharmacy Services in Telepharmacy: how is it working, where is it working, and what is required to practice in this new setting Michelle Rundquist1 and Aimee Skrei1 1University of Minnesota College of Pharmacy, Minneapolis, MN, USA June 2017 Abstract Telepharmacy is a rapidly growing area of communication within pharmaceutical care delivery, es- pecially in rural areas. The purpose of this literature review was to determine where telepharmacy is currently being practiced within community and ambulatory pharmacy settings and the effectiveness of it. Additionally, state rules and regulations for the upper Midwest region were compared and con- trasted to analyze how specific states are addressing the use of telepharmacy practice within the specified settings. -
Telepharmacy Rules and Statutes: a 50-State Survey
American Journal of Medical Research 5(2), 2018 pp. 7–23, ISSN 2334-4814, eISSN 2376-4481 doi:10.22381/AJMR5220181 TELEPHARMACY RULES AND STATUTES: A 50-STATE SURVEY GEORGE TZANETAKOS Department of Health Management and Policy, College of Public Health, The University of Iowa FRED ULLRICH Department of Health Management and Policy, College of Public Health, The University of Iowa KEITH MUELLER [email protected] Department of Health Management and Policy, College of Public Health, The University of Iowa (corresponding author) ABSTRACT. There has been a significant decline in the number of independently owned rural pharmacies serving non-metropolitan areas, thereby limiting access to pharmaceutical services for rural residents, particularly for those most vulnerable and in need of these services. The use of telepharmacy is one potential solution to this problem. Telepharmacies deliver pharmaceutical care to outpatients at a distance via telecommunication and other advanced technologies. This study identifies rules and laws enacted by states authorizing the use of community telepharmacy initiatives within their respective jurisdictions. As of August 2016, the use of telepharmacy was authorized, in varying capacities, in 23 states (46%). Pilot program development that could apply to telepharmacy initiatives was authorized by six states (12%). Waivers to administrative or legislative pharmacy practice requirements that could allow for telepharmacy initiatives were permitted in five states (10%). Nearly one-third of the states (16, or 32%) did not authorize the use of telepharmacy, nor did they authorize the pursuit of telepharmacy initiatives via pilot programs or waivers. Keywords: telepharmacy; rule; statute; rural; community; outpatient How to cite: Tzanetakos, George, Fred Ullrich, and Keith Mueller (2018). -
ACCP Toolkit the 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit
ACCP Toolkit The 2016 ACCP Pharmacotherapy Didactic Curriculum Toolkit 2016 Educational Afairs Committee, American College of Clinical Pharmacy Terry L. Schwinghammer (Chair), Andrew J. Crannage (Vice Chair), Eric G. Boyce, Bridget Bradley, Alyssa Christensen, Henry M. Dunnenberger, Michelle Fravel, Holly Gurgle, Drayton A. Hammond, Jennifer Kwon, Douglas Slain, and Kurt A. Wargo. Approved by the American College of Clinical Pharmacy Board of Regents on July 18, 2016. The purpose of the 2009 and 2016 ACCP Pharmacother- ORGAN SYSTEMS AND DISEASE STATE TOPICS apy Didactic Curriculum Toolkits is to provide guid- ance to schools and colleges of pharmacy in developing, Cardiovascular Disorders maintaining, and modifying their curricula.1,2 The 2016 1 Acute coronary syndromes (STEMI, NSTEMI, unstable ACCP Educational Affairs Committee reviewed recent angina) medical literature and other documents to identify dis- 1 Atherosclerotic cardiovascular disease, primary ease states that are responsive to drug therapy. Disease prevention frequency, socioeconomic burden to society, and impact 1 Atherosclerotic cardiovascular disease, secondary of pharmacist involvement in medication therapy were prevention considered in determining which topics to include in the updated pharmacotherapy toolkit. This updated toolkit 1 Arrhythmias, atrial (e.g., atrial fbrillation) is intended to provide valuable guidance to schools and 1 Basic life support (BLS) colleges of pharmacy as they develop, maintain, and 1 Dyslipidemia modify their curricula to keep pace with major scientific 1 Heart failure, chronic advances and practice changes. 1 Hypertension In the 2016 toolkit, diseases and content topics are 1 Ischemic heart disease, stable organized by organ system, when feasible, and grouped 1 Venous thromboembolism into tiers defined by practice competency. -
Annual Report 2019 TABLE of CONTENTS
Hamdard University Islamabad Campus Annual Report 2019 TABLE OF CONTENTS Contents Page No The Founder 1 Message from Director General 3 Vision of Hamdard University 4 Mission of Hamdard University 4 Hamdard University Islamabad Campus 4 Highlights of Year 2019 5 HUIC Organizational Chart 6 Academic Performance 7 Admissions 2019 7 Recognition of Academic Programs 7 Number of Graduates 8 Library at HUIC 9 Office of Student Affairs 12 Hamdard Institute of Management Sciences 15 Hamdard Institute of Engineering and Technology 21 Hamdard Institute of Pharmaceutical Sciences 27 HAMDARD UNIVERSITY ISLAMABAD CAMPUS ANNUAL REPORT 2019 The Founder Shaheed Hakim Mohammed Said (1920-1998) established Hamdard Pakistan in 1948. Within a few years, the herbal medical products of Hamdard became household names. The phenomenal success of Hamdard products is a legendary part of the business history of Pakistan. The name Hamdard however acquired a still wider meaning, when Hakim Mohammed Said founded Hamdard University in 1991. The establishment of a university which could enliven the intellectual tradition of the educational institutions of the golden era of Muslim civilization had always been his most cherished dream.In fact it was the central point towards which all his endeavours were directed. The actual appearance of the university was just the culmination of a long dedicated and continued effort spanning his whole life. However, apart from being a great educational leader, Hakim Mohammed Said was also one of the finest exponents of eastern medicine, who had treated millions of patients from all over the world including Pakistan, Europe,Africa and the Middle East by the time of his martyrdom (Shahadat) in October 1998. -
Pharmacotherapy for Adults with Alcohol Use Disorder in Outpatient
Pharmacotherapy for Adults With Alcohol Use KEYDisorder ISSUE in Outpatient Settings Medications can be effective in treating alcohol use disorder Summary of Evidence From the Systematic Review (AUD) when used in combination with psychosocial interventions. üüAcamprosate and oral naltrexone improve alcohol consumption Evidence from epidemiological studies suggests that improving outcomes for patients with AUD. Head-to-head trials have not alcohol consumption outcomes (such as reduction in return to consistently established the superiority of one medication over drinking or in percentage of drinking days) would likely result in another. (See Table 1.) improved health outcomes. However, medications are underutilized üüEvidence related to injectable naltrexone is currently limited. in treating AUD, thus providing opportunities for expanding treatment optimization. This is a summary of a systematic review üüEvidence from randomized controlled trials does not support evaluating the efficacy, comparative effectiveness, and adverse the efficacy of disulfiram. effects of medications in adults with AUD. The systematic »üDisulfiram may be recommended to individuals who have review included 167 articles published from January 1, 1970, a goal of abstinence but for whom acamprosate and oral to October 11, 2013. The full report, listing all studies, is available naltrexone are not suitable or to individuals who prefer at www.effectivehealthcare.ahrq.gov/alcohol-disorder. disulfiram and understand its risks.4 BACKGROUND üüMost studies evaluated medications